John L. Marshall
MD
Chief, Division of Hematology/Oncology; Director, Ruesch Center for the Cure of Gastrointestinal Cancers; Professor of Medicine
👥Biography 个人简介
John L. Marshall, MD is Chief of the Division of Hematology/Oncology, Director of the Ruesch Center for the Cure of Gastrointestinal Cancers, and Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center. Over nearly three decades, he has been a central figure in clinical trials for colorectal cancer, a prolific drug developer, and one of the most visible physician-scientists in American GI oncology. Dr. Marshall contributed to the QUASAR (Quick and Simple and Reliable) trial, the large international randomized trial that provided definitive evidence for the benefit of adjuvant fluorouracil/leucovorin in stage II colon cancer—a long-debated question in oncology—and established clear survival benefit, influencing NCCN and ASCO guideline recommendations. He has also led numerous early-phase and phase III trials evaluating novel therapeutics in mCRC, including antiangiogenic agents, EGFR inhibitors, cancer vaccines, and combination immunotherapy strategies. A nationally recognized leader in cancer drug development, Dr. Marshall has been involved in more than 100 clinical trials and is a prolific author and sought-after educator. He founded and directs one of the most productive GI cancer research programs on the East Coast, and has been a leading voice on oncology drug access, clinical trial design, and the future of GI cancer care. He is widely known for his accessible communication style and commitment to patient education.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
QUASAR Trial: 5-FU Adjuvant Therapy in Stage II Colon Cancer
Contributed to the QUASAR (Quick and Simple and Reliable) trial, the large randomized study providing definitive quantification of the absolute survival benefit from adjuvant fluorouracil/leucovorin in stage II colon cancer, directly addressing the long-debated question of adjuvant treatment benefit in this setting and informing risk-adapted guideline recommendations.
Novel Drug Development in mCRC
Led multiple early-phase and phase II/III trials evaluating novel agents in metastatic colorectal cancer, including antiangiogenic agents, EGFR inhibitors, cancer vaccines (PANVAC), and combination immunotherapy strategies, contributing to the evidence base for several FDA-approved agents.
Georgetown Ruesch Center GI Oncology Research Program
Founded and directed the Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi, building one of the most active GI oncology research programs in the eastern United States with a focus on translational science, clinical trials, and patient advocacy.
Cancer Drug Access and Patient Education
Championed transparent communication about cancer treatment options, drug costs, and clinical trial access, authoring lay publications and media appearances to educate patients and the public about GI cancer care, and contributing to policy discussions on oncology drug affordability.
Representative Works 代表性著作
Adjuvant Chemotherapy versus Observation in Patients with Colorectal Cancer: A Randomised Study (QUASAR)
The Lancet (2007)
Large randomized QUASAR trial definitively quantifying the survival benefit of adjuvant fluorouracil/leucovorin in stage II colon cancer, providing the clearest evidence to that point supporting adjuvant therapy in this stage and informing a decade of guideline discussions about stage II treatment decisions.
A Randomized Phase II Study of PANVAC-VF (Vaccinia) as Adjuvant Therapy in Patients with Resected Pancreatic and Colorectal Cancers
Clinical Cancer Research (2011)
Phase II trial of CEA/MUC-1-targeted poxvirus cancer vaccine (PANVAC-VF) in the adjuvant setting in resected GI cancers, investigating the potential of therapeutic vaccination to reduce recurrence.
Cetuximab plus Irinotecan, Fluorouracil, and Leucovorin as First-Line Therapy for Metastatic Colorectal Cancer
Journal of Clinical Oncology (2007)
Phase II study establishing the feasibility and clinical activity of cetuximab combined with FOLFIRI in first-line mCRC, contributing to the evidence base for anti-EGFR plus chemotherapy combinations.
Management of Metastatic Colorectal Cancer: Current Standards and Emerging Strategies
Journal of the National Comprehensive Cancer Network (2020)
Comprehensive review of evidence-based and emerging treatment strategies in mCRC, covering first- through later-line therapies and providing practical guidance on sequencing, biomarker testing, and novel agent integration.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-05 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 John L. Marshall 的研究动态
Follow John L. Marshall's research updates
留下邮箱，当我们发布与 John L. Marshall（Georgetown Lombardi Comprehensive Cancer Center, Georgetown University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment